ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
Giavina-Bianchi et al., Journal of Allergy and Clinical Immunology: Global, doi:10.1016/j.jacig.2023.100140
https://c19early.org/giavinabianchi.html